Suppr超能文献

印度肝细胞癌的流行病学——2024年最新综述

Epidemiology of Hepatocellular Carcinoma in India - An Updated Review for 2024.

作者信息

Giri Suprabhat, Singh Ankita

机构信息

Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar, India.

Department of Gastroenterology, Seth GS Medical College and KEM Hospital, Mumbai, India.

出版信息

J Clin Exp Hepatol. 2024 Nov-Dec;14(6):101447. doi: 10.1016/j.jceh.2024.101447. Epub 2024 May 21.

Abstract

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and is a significant cause of morbidity and mortality, especially in patients with chronic liver disease. As a reflection of geographical variations in India, there is significant variation in the prevalence and etiological factors of HCC. In contrast to previous studies reporting viral hepatitis as the most common etiology, recent data indicates a changing etiological pattern of cirrhosis and HCC, with alcohol and metabolic dysfunction-associated steatotic liver disease (MASLD) emerging as the foremost cause. Thus, there was a need for an updated review of the current literature and databases for the changing epidemiology and etiological spectrum of HCC in India. The review included data primarily from the National Cancer Registry Program and the Global Burden of Diseases, Injuries, and Risk Factors Study, with the inclusion of other studies from India. The highlights of the present review are summarized in the following lines. Although the current incidence (2.15 per 100,000), prevalence (2.27 per 100,000), and mortality (2.21 per 100,000) rate of HCC in India remain lower compared to the global data, the annual rates of change in these parameters are higher in India. Among Indians, the present incidence, prevalence, and mortality related to HCC are higher in males, while the annual rate of change is higher in females. The Northeastern states have higher incidence, prevalence, and mortality related to HCC, but the Western states of Gujarat, Maharashtra, Goa, and Kerala are emerging as newer hotspots with higher annual rates of change in incidence, prevalence, and mortality. The incidence of HCC related to hepatitis B is on a downtrend, while those related to alcohol and MASLD are rising. Public health initiatives, awareness campaigns, and focused treatments are all necessary to combat these changes, particularly in areas with high incidence rates.

摘要

肝细胞癌(HCC)是原发性肝癌最常见的形式,是发病和死亡的重要原因,尤其是在慢性肝病患者中。作为印度地理差异的一种体现,HCC的患病率和病因因素存在显著差异。与之前报告病毒性肝炎为最常见病因的研究不同,最近的数据表明肝硬化和HCC的病因模式正在发生变化,酒精和代谢功能障碍相关脂肪性肝病(MASLD)成为首要病因。因此,有必要对当前文献和数据库进行更新回顾,以了解印度HCC不断变化的流行病学和病因谱。该综述主要纳入了来自国家癌症登记计划和全球疾病、伤害及风险因素研究的数据,并纳入了印度的其他研究。本综述的要点总结如下。尽管印度目前HCC的发病率(每10万人2.15例)、患病率(每10万人2.27例)和死亡率(每10万人2.21例)与全球数据相比仍然较低,但这些参数的年变化率在印度更高。在印度人中,目前与HCC相关的发病率、患病率和死亡率在男性中较高,而年变化率在女性中较高。东北部各邦与HCC相关的发病率、患病率和死亡率较高,但古吉拉特邦、马哈拉施特拉邦、果阿邦和喀拉拉邦等西部邦正成为新的热点地区,其发病率、患病率和死亡率的年变化率更高。与乙型肝炎相关的HCC发病率呈下降趋势,而与酒精和MASLD相关的发病率呈上升趋势。开展公共卫生倡议、提高认识运动和针对性治疗对于应对这些变化都是必要的,特别是在发病率高的地区。

相似文献

1
Epidemiology of Hepatocellular Carcinoma in India - An Updated Review for 2024.
J Clin Exp Hepatol. 2024 Nov-Dec;14(6):101447. doi: 10.1016/j.jceh.2024.101447. Epub 2024 May 21.
2
NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements. 2002;19(3):1-46.
4
Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040.
JAMA Netw Open. 2024 Nov 4;7(11):e2445525. doi: 10.1001/jamanetworkopen.2024.45525.
6
Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Health Technol Assess. 2007 Sep;11(34):1-206. doi: 10.3310/hta11340.
7
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.
Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948.
8
Changing Etiological Spectrum of Hepatocellular Carcinoma in India-A Systematic Review and Meta-analysis.
J Clin Exp Hepatol. 2024 Sep-Oct;14(5):101391. doi: 10.1016/j.jceh.2024.101391. Epub 2024 Mar 4.
9
Hepatocellular carcinoma in patients without cirrhosis.
World J Gastroenterol. 2025 Jun 21;31(23):107100. doi: 10.3748/wjg.v31.i23.107100.

引用本文的文献

2
Nuclear factor IA-mediated transcriptional regulation of crystallin αB inhibits hepatocellular carcinoma progression.
Mol Clin Oncol. 2025 Jun 20;23(2):72. doi: 10.3892/mco.2025.2867. eCollection 2025 Aug.
4
Roadmap for HCC Surveillance and Management in the Asia Pacific.
Cancers (Basel). 2025 Jun 10;17(12):1928. doi: 10.3390/cancers17121928.
5
Managing Complex Hepatocellular Carcinoma Subtypes: Diffuse Infiltrative, Large Tumours, and Tumour Rupture-The Challenges and Strategies.
J Clin Exp Hepatol. 2025 May-Jun;15(3):102505. doi: 10.1016/j.jceh.2025.102505. Epub 2025 Jan 22.
9
International perspectives on LI-RADS.
Abdom Radiol (NY). 2024 Dec 19. doi: 10.1007/s00261-024-04729-3.

本文引用的文献

1
Changing Etiological Spectrum of Hepatocellular Carcinoma in India-A Systematic Review and Meta-analysis.
J Clin Exp Hepatol. 2024 Sep-Oct;14(5):101391. doi: 10.1016/j.jceh.2024.101391. Epub 2024 Mar 4.
2
Etiological Spectrum of Cirrhosis in India: A Systematic Review and Meta-analysis.
J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101291. doi: 10.1016/j.jceh.2023.10.002. Epub 2023 Oct 9.
4
National viral hepatitis control program in India: Call for update.
J Family Med Prim Care. 2023 Sep;12(9):1755-1758. doi: 10.4103/jfmpc.jfmpc_1455_23. Epub 2023 Sep 30.
5
Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes.
Cancer Rep (Hoboken). 2023 Sep;6 Suppl 1(Suppl 1):e1821. doi: 10.1002/cnr2.1821. Epub 2023 Jun 21.
6
Multi-center prospective survey of hepatocellular carcinoma in Kerala: More than 1,200 cases.
Indian J Gastroenterol. 2023 Apr;42(2):233-240. doi: 10.1007/s12664-022-01314-8. Epub 2023 May 8.
9
Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India.
Indian J Med Res. 2022 Oct-Nov;156(4&5):598-607. doi: 10.4103/ijmr.ijmr_1821_22.
10
Clinical Profile, Patterns of Care & adherence to Guidelines in Patients with Hepatocellular Carcinoma: Prospective multi-center Study.
J Clin Exp Hepatol. 2022 Nov-Dec;12(6):1463-1473. doi: 10.1016/j.jceh.2022.05.006. Epub 2022 Jun 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验